– UK, Weybridge – Haleon plc (LON: HLN / NYSE: HLN) today announced the appointment of Bláthnaid Bergin to its Board as an independent Non-Executive Director effective on 24 February 2025, to bring financial leadership and strategic planning experience from a variety of consumer-facing businesses.
“I would like to thank Dave for his insights and contributions to the Board’s discussions. We wish him all the very best for the future. I would like to welcome Bláthnaid to Haleon. With her strong track record of financial leadership and transformation from multiple consumer-facing businesses, Bláthnaid brings a wealth of relevant skills and experience to the Board.” said Board Chair, Sir Dave Lewis.
Following the reduction of Pfizer Inc.’s shareholding Non-Executive Director David Denton representative of Pfizer Inc. stepped down from the Board on 4 December 2024.
About Bláthnaid Bergin
Bláthnaid Bergin is CFO of J Sainsbury plc, where she has played a pivotal role in driving the company’s financial strategy and operational efficiency initiatives. Before joining Sainsbury’s, Bláthnaid held senior finance leadership and international positions at Aviva, RSA, and GE working across Europe, Asia, and Australia. She is a Chartered Accountant. Bláthnaid was previously a Non-Executive Director, Chair of the Audit Committee, and Senior Independent Director for Artemis Alpha Investment Trust.
About Haleon
Haleon is a global leader in consumer health, in delivering better everyday health to humanity. Haleon’s product portfolio spans five major categories – Oral Health, Pain Relief, Respiratory Health, Digestive Health and others, and Vitamins, Mineral, and Supplements. Its long-standing brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polidentperiodontalax, and Centrum – are built on trusted science, innovation, and deep human understanding.
For more: https://www.haleon.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.